Molecular engineering and plant expression of an immunoglobulin heavy chain scaffold for delivery of a dengue vaccine candidate
Open Access
- 15 July 2017
- journal article
- Published by Wiley in Plant Biotechnology Journal
- Vol. 15 (12) , 1590-1601
Abstract
Summary: In order to enhance vaccine uptake by the immune cells in vivo, molecular engineering approach was employed to construct a polymeric immunoglobulin G scaffold (PIGS) that incorporates multiple copies of an antigen and targets the Fc gamma receptors on antigen‐presenting cells. These self‐adjuvanting immunogens were tested in the context of dengue infection, for which there is currently no globally licensed vaccine yet. Thus, the consensus domain III sequence (cEDIII) of dengue glycoprotein E was incorporated into PIGS and expressed in both tobacco plants and Chinese Ovary Hamster cells. Purified mouse and human cEDIII‐PIGS were fractionated by HPLC into low and high molecular weight forms, corresponding to monomers, dimers and polymers. cEDIII‐PIGS were shown to retain important Fc receptor functions associated with immunoglobulins, including binding to C1q component of the complement and the low affinity Fcγ receptor II, as well as to macrophage cells in vitro. These molecules were shown to be immunogenic in mice, with or without an adjuvant, inducing a high level IgG antibody response which showed a neutralizing potential against the dengue virus serotype 2. The cEDIII‐PIGS also induced a significant cellular immune response, IFN‐γ production and polyfunctional T cells in both the CD4+ and CD8+ compartments. This proof‐of‐principle study shows that the potent antibody Fc‐mediated cellular functions can be harnessed to improve vaccine design, underscoring the potential of this technology to induce and modulate a broad‐ranging immune response.Keywords
Funding Information
- Ministry of Education, Science and Technology (2013R1A6A3A03022769, NRF-2014K1B1A1073861)
This publication has 48 references indexed in Scilit:
- Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic DiseaseNew England Journal of Medicine, 2015
- The dengue vaccine pipeline: Implications for the future of dengue controlVaccine, 2015
- Novel vaccination approach for dengue infection based on recombinant immune complex universal platformVaccine, 2015
- SPICE: Exploration and analysis of post‐cytometric complex multivariate datasetsCytometry Part A, 2011
- Domain III of the envelope protein as a dengue vaccine targetExpert Review of Vaccines, 2010
- Generation of glyco‐engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human‐like N‐glycan structurePlant Biotechnology Journal, 2008
- Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania majorNature Medicine, 2007
- Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minorNature Biotechnology, 2006
- A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primatesVaccine, 2006
- Aluminium Hydroxide Adjuvant Initiates Strong Antigen-Specific Th2 Responses in the Absence of IL-4- or IL-13-Mediated SignalingThe Journal of Immunology, 1999